AABB shapes legislative and regulatory policies that support safety and innovation. The Association engages policymakers, providers, suppliers, manufacturers and patient groups to promote patient and donor care and safety in transfusion medicine and cellular therapies.
AABB Asks FDA to Clarify That Proposed LDT Regulations Will Not Apply to Relationship Testing
December 06, 2023
Blood Community Urges FDA to Exclude Blood Products From PMI Requirements
December 05, 2023
Take Action: AABB Initiates New Action Alert to Oppose Proposed FDA Rule Regulating LDTs
November 08, 2023